共 28 条
[1]
BMS2345541 is a highly se-lective inhibitor of I kappa B kinase that binds at an allosteric site of theenzyme and blocks NF-kappa B-dependent transcription in mice. Burke J R,Pattoli MA,Gregor KR,et al. Journal of Biological Chemistry . 2003
[2]
Efficacy of oral long-termN-acetylcysteine in chronic bronchopulmonary disease:a meta-analysis ofpublished double-blind,placebo-controlled clinical trials. Grandjean EM,Berthet P,Ruffmann R,et al. Clin T-her . 2000
[3]
Cilomilast,a selective phos-phodiesterase-4 inhibitor for treatment of patients with chronic obstructivepulmonary disease:a randomised,dose-ranging study. Compton CH,Gubb J,Nieman R,et al. The Lancet . 2001
[4]
Oxidants/antioxidants and COPD. Macnee W. Chest . 2000
[5]
The interrelationsh ip of sputum in-flammatory markers in patients w ith chron ic bronch itis. H ill AT,Bayley D,Stockley RA. Am J Resp irC rit Care M ed . 1999
[6]
Interleukin-8 receptor antagonists in pulmonarydiseases. Hay DWP,Sarau HM. Current Opinion in Pharmacology . 2001
[7]
lA random ized controlled com-parison of tiotrop ium and ipratrop ium in the treatm ent of chron ic obstruc-tive pu lmonary d isease. Noord JAV,Bantje TA,E land ME,et a. Thorax . 2000
[8]
Design of selectiveand soluble inhibitors of tumor necrosis factor-α?converting enzyme(TACE). Rabinowitz MH,Andrews RC,Becherer JD,et al. Journal of Medicinal Chemistry . 2001
[9]
Ariflo(SB 207499),asecond generation phosphodiesterase 4 inhibitor for the treatment of asth-ma and COPD:fromconcept to clinic. Torphy TJ,Barnette MS,Underwood DC,et al. Pulmonary Pharmacology and Therapeutics . 1999
[10]
Differences in interleukin-8and tumor necrosis factor-α?in induced sputumfrompatients with chro-nic obstructive pulmonary disease or asthma. Keatings VM,Collins PD,Scott DM,et al. American Journal of Respiratory and Critical Care Medicine . 1996